top of page

News & Events

14 June 2024

HaemaLogiX presents important new pre-clinical data at EHA2024 in Madrid

Image-empty-state_edited_edited_edited.j

14 June 2024

19 May 2024

HaemaLogiX welcomes former Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director

Image-empty-state_edited_edited_edited.j

19 May 2024

5 May 2024

HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum

Image-empty-state_edited_edited_edited.j

5 May 2024

28 February 2024

Honouring Rare Disease Day: The Battle Against Multiple Myeloma and AL Amyloidosis

Image-empty-state_edited_edited_edited.j

28 February 2024

31 January 2024

HaemaLogiX announces appointment of Laurence Turka, M.D. as a Non-Executive Director

Image-empty-state_edited_edited_edited.j

31 January 2024

30 January 2024

HaemaLogiX appoints haematologist Angela Dispenzieri, M.D. to its Scientific Advisory Board

Image-empty-state_edited_edited_edited.j

30 January 2024

15 January 2024

HaemaLogiX announces issuance of South Korean patent for KMA.CAR-T

Image-empty-state_edited_edited_edited.j

15 January 2024

3 January 2024

Dr. John Cullity Appointed Chairman of HaemaLogiX

Image-empty-state_edited_edited_edited.j

3 January 2024

10 December 2023

HaemaLogiX’s CMDO Tertia Dex to speak at 2nd Australia Biologics Festival 2024

Image-empty-state_edited_edited_edited.j

10 December 2023

13 November 2023

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

Image-empty-state_edited_edited_edited.j

13 November 2023

30 October 2023

HaemaLogiX announces issuance of Israeli patent for KMA.CAR-T

Image-empty-state_edited_edited_edited.j

30 October 2023

16 October 2023

HaemaLogiX's CSO, Dr. Rosanne Dunn, presents at Cell and Gene Therapy World Asia, Singapore

Image-empty-state_edited_edited_edited.j

16 October 2023

8 October 2023

Two posters, highlighting HaemaLogiX results, were presented at International Myeloma Society, Athens

Image-empty-state_edited_edited_edited.j

8 October 2023

25 July 2023

HaemaLogiX to take KMA.CAR-T to Ph1 trial with Peter Mac

Image-empty-state_edited_edited_edited.j

25 July 2023

28 June 2023

Positive final KappaMab Ph2b study results announced

Image-empty-state_edited_edited_edited.j

28 June 2023

19 June 2023

June 2023 newsletter

Image-empty-state_edited_edited_edited.j

19 June 2023

15 June 2023

HaemaLogiX abstract accepted for publication at the International Conference on Malignant Lymphoma

Image-empty-state_edited_edited_edited.j

15 June 2023

14 June 2023

Watch: Inside the KappaMab manufacturing process

Image-empty-state_edited_edited_edited.j

14 June 2023

30 May 2023

Watch: Karen Wilde, myeloma patient story

Image-empty-state_edited_edited_edited.j

30 May 2023

23 May 2023

Watch: Our value inflection points between Q2 2023 and FY 2024

Image-empty-state_edited_edited_edited.j

23 May 2023

16 May 2023

Watch: The competitive advantage of our immunotherapies explained

Image-empty-state_edited_edited_edited.j

16 May 2023

9 May 2023

Watch: Meet our team: Dr Geoffrey Nichol

Image-empty-state_edited_edited_edited.j

9 May 2023

2 May 2023

Watch: For investors, interview series with Dr Geoffrey Nichol

Image-empty-state_edited_edited_edited.j

2 May 2023

27 April 2023

Poster presentation at 2023 AACR meeting

Image-empty-state_edited_edited_edited.j

27 April 2023

3 April 2023

HaemaLogiX announces issuance of Japanese patent for KMA.CAR-T

Image-empty-state_edited_edited_edited.j

3 April 2023

21 December 2022

Watch: The latest on our CAR-T technology at Myeloma Australia’s 4th Workshop

Image-empty-state_edited_edited_edited.j

21 December 2022

20 December 2022

Watch: Our CSO Dr Rosanne Dunn presenting on our novel antigens LMA and KMA at ASH 2022

Image-empty-state_edited_edited_edited.j

20 December 2022

15 December 2022

Watch: What makes our immunotherapies different on the growing myeloma treatment market

Image-empty-state_edited_edited_edited.j

15 December 2022

17 October 2022

AusBiotech 2022: HaemaLogiX CEO Bryce Carmine to present

Image-empty-state_edited_edited_edited.j

17 October 2022

12 October 2022

Watch: Everything you need to know about HaemaLogiX right now, CEO interview

Image-empty-state_edited_edited_edited.j

12 October 2022

11 October 2022

HaemaLogiX’s CAR-Ts to feature at 4th National Myeloma Workshop

Image-empty-state_edited_edited_edited.j

11 October 2022

27 September 2022

HaemaLogiX announces issuance of US patent for LMA

Image-empty-state_edited_edited_edited.j

27 September 2022

15 August 2022

Watch: Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

Image-empty-state_edited_edited_edited.j

15 August 2022

7 July 2022

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

Image-empty-state_edited_edited_edited.j

7 July 2022

7 July 2022

HaemaLogiX announces issuance of USA patent for KMA.CAR-T

Image-empty-state_edited_edited_edited.j

7 July 2022

27 January 2022

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Image-empty-state_edited_edited_edited.j

27 January 2022

bottom of page